Skip to main content
Clinical Trials/NCT03147690
NCT03147690
Terminated
Phase 1

A Multicenter Trial of Contrast-Enhanced Ultrasound in the Evaluation of Abdominal Solid Organ Injuries in Pediatric Trauma

David Mooney8 sites in 1 country74 target enrollmentNovember 1, 2017
InterventionsLumason
DrugsLumason

Overview

Phase
Phase 1
Intervention
Lumason
Conditions
Abdominal Injury
Sponsor
David Mooney
Enrollment
74
Locations
8
Primary Endpoint
Proportion of Patients for Whom All Organs Identified by CT With Injuries Are Also Identified by CEUS, Regardless of Injury Grade.
Status
Terminated
Last Updated
4 years ago

Overview

Brief Summary

This study proposes to evaluate the accuracy of contrast-enhanced ultrasound (CEUS) in diagnosing abdominal solid organ injuries in pediatric patients. 146 subjects will be enrolled across approximately 8 sites in the US. All subjects will have had a Computerized Tomography (CT) scan as part of standard of care, confirming at least one solid organ abdominal injury. All subjects will have an abdominal ultrasound without contrast, followed by a contrast-enhanced ultrasound using the contrast agent Lumason. Ultrasound and contrast-enhanced ultrasound results will be compared to the CT scan results. The study procedures will take place within 48 hours of injury.

Detailed Description

This is an interventional study proposes to evaluate the accuracy of contrast-enhanced ultrasound (CEUS) in diagnosing abdominal solid organ injuries in pediatric patients. 146 subjects will be enrolled across approximately 8 sites in the US. All subjects will have had a Computerized Tomography (CT) scan as part of standard of care, confirming at least one solid organ abdominal injury. All subjects will have an abdominal ultrasound without contrast, followed by a contrast-enhanced ultrasound using the contrast agent Lumason. Ultrasound and contrast-enhanced ultrasound results will be compared to the CT scan results. The study procedures will take place within 48 hours of injury. At conclusion of enrollment of all subjects a centralized review of CT vs. CEUS will occur to compare to real time readings.

Registry
clinicaltrials.gov
Start Date
November 1, 2017
End Date
October 7, 2019
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

David Mooney

Director Trauma Program

Boston Children's Hospital

Eligibility Criteria

Inclusion Criteria

  • Hemodynamically stable, as determined by the trauma team
  • Age 8 through 17 years
  • Interpretable CT of the abdomen and pelvis that demonstrates at least one abdominal solid organ injury among the liver, spleen, pancreas, and kidneys
  • Plan for observation or admission to the hospital
  • Candidate for abdominal ultrasound based on body habitus
  • Have a Glasgow Coma Score of 15
  • Able to complete the study procedures within 48 hours of injury

Exclusion Criteria

  • Known cardiac abnormality
  • Pulmonary hypertension
  • Known sensitivity to sulfur hexafluoride, polyethylene glycol 4000, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylglycerol sodium (DPPG-Na), or palmitic acid
  • Unable to roll over
  • Unable to assent
  • Lactating
  • CT images not available for transmission to central image repository

Arms & Interventions

All Study Participants

All subjects will have an abdominal non-contrast ultrasound performed. Lumason will then be administered at a dose of 0.03mL/kg up to a maximum dose of 2.4mL and a contrast-enhanced ultrasound will be performed. The dose will be given twice, for a total maximum dose per subject of 4.8mL

Intervention: Lumason

Outcomes

Primary Outcomes

Proportion of Patients for Whom All Organs Identified by CT With Injuries Are Also Identified by CEUS, Regardless of Injury Grade.

Time Frame: At the time the CEUS is performed, within 48 hours of injury.

During analysis, results of contrast enhanced ultrasound will be compared to results of CT scan that was performed as part of clinical care to determine if the organs identified as injured by CT were also identified as injured by CEUS.

Secondary Outcomes

  • For Each Organ, the Proportion of Patients for Whom the Organ is Identified by CT and CEUS as Injured (Regardless of Grade).(At the time the CEUS is performed, within 48 hours of injury.)
  • Proportion of Injuries Identified by CEUS Which Are Within 1 Grade of the Injury Identified by CT.(At the time the CEUS is performed, within 48 hours of injury.)
  • Proportion of Patients Where the Absence or Presence of Peritoneal Fluid Identified by CT is Also Identified by CEUS.(At the time the CEUS is performed, within 48 hours of injury.)
  • Proportion of Patients With Agreement Between 'Real-time' and Centralized Interpretation of CEUS Images.(At the time the CEUS is performed, within 48 hours of injury.)

Study Sites (8)

Loading locations...

Similar Trials